Biologics From Within
Developing a non-viral gene therapy to protect people against COVID-19
Color-enhanced electron microscopic image courtesy of National Institutes of Health.
Ultrastructural morphology of SARS-CoV-2, courtesy of the CDC.
SmartPharm’s gene-encoded therapeutics (GET) approach has multiple benefits compared to traditional viral-vectored gene therapy:
Minimally immunogenic; does not require immune suppression
Re-dosable in patients
Scalable, economic cGMP manufacturing
Reduced regulatory complexity
SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.